Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Non-Current Assets (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Non-Current Assets for 16 consecutive years, with $454.5 million as the latest value for Q1 2026.

  • Quarterly Non-Current Assets fell 3.09% to $454.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 billion through Jan 2026, up 67.16% year-over-year, with the annual reading at $454.5 million for FY2026, 3.09% down from the prior year.
  • Non-Current Assets for Q1 2026 was $454.5 million at Usana Health Sciences, down from $462.5 million in the prior quarter.
  • The five-year high for Non-Current Assets was $472.7 million in Q2 2025, with the low at $85.2 million in Q2 2022.
  • Average Non-Current Assets over 5 years is $265.4 million, with a median of $214.9 million recorded in 2022.
  • Peak annual rise in Non-Current Assets hit 155.98% in 2022, while the deepest fall reached 56.61% in 2022.
  • Over 5 years, Non-Current Assets stood at $212.2 million in 2022, then grew by 1.34% to $215.0 million in 2023, then soared by 118.13% to $469.0 million in 2024, then decreased by 1.38% to $462.5 million in 2025, then decreased by 1.73% to $454.5 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $454.5 million, $462.5 million, and $472.7 million for Q1 2026, Q3 2025, and Q2 2025 respectively.